Enhanced Phospho-Epitope Detection for Mitotic Analysis
The invention is a rat monoclonal antibody specifically targeting the phosphorylated Ser83 site of 4E-BP1 (p4E-BP1 S83), enabling precise and reliable assessment of mitotic index with enhanced specificity and reduced background staining in cellular and tissue analyses.
Description
This technology revolves around a novel rat-derived monoclonal antibody engineered to bind selectively to the phosphorylated Ser83 residue on the eukaryotic translation initiation factor 4E-binding protein 1 (4E-BP1). The S83 phosphorylation site is a critical marker involved in cell cycle regulation, particularly during mitosis. Unlike existing polyclonal antibodies, which are prone to non-specific interactions resulting in background noise, this monoclonal antibody exhibits high affinity and specificity towards the p4E-BP1 S83 epitope, ensuring cleaner immunostaining results. The antibody's binding enables researchers to precisely identify and quantify mitotic cells within heterogeneous populations, thereby facilitating accurate determination of the mitotic index—a crucial parameter for understanding cell proliferation and division dynamics in both normal and pathological contexts. The technology is applied through standard immunohistochemical and immunocytochemical techniques, including Western blotting and immunofluorescence staining, providing robust compatibility with various experimental platforms.Applications
- Quantitative measurement of mitotic index in cancer research to evaluate tumor proliferation rates.- Use in drug development pipelines to assess the efficacy of anti-mitotic agents by monitoring changes in mitotic activity.
- Application in pathology laboratories for enhanced diagnostic accuracy in tissue biopsies through improved mitotic cell detection.
- Basic cell biology research studying cell cycle regulation and signal transduction pathways involving 4E-BP1 phosphorylation.
- Validation and standardization of cell line models by providing a reliable marker for mitotic status.
- Potential utility in biomarker discovery and validation where mitotic index serves as a prognostic or predictive indicator.
Advantages
- High Specificity: The monoclonal nature and targeted epitope recognition reduces cross-reactivity and non-specific staining common with polyclonal antibodies, leading to more accurate results.- Enhanced Sensitivity: Improved affinity for the p4E-BP1 S83 phosphorylation site facilitates detection even at low phosphorylation levels, beneficial for early-stage cellular events analysis.
- Reproducibility: As a monoclonal antibody, it ensures batch-to-batch consistency, critical for comparative studies and longitudinal experiments.
- Versatility: Demonstrates compatibility across multiple assay types, including immunohistochemistry, immunocytochemistry, and Western blotting, allowing integration into standard laboratory workflows.
- Commercial Interest: Early commercial interest underscores the perceived market value and potential adoption in research and clinical settings.
- Reduced Background Noise: Minimization of non-specific staining enhances clarity in imaging and quantification, reducing false positives and improving data integrity.